Soligenix Boosts Manufacturing Capabilities with U.S. Transfer

Soligenix shares are trading higher after the company successfully completed the U.S. transfer of the manufacturing process for its synthetic hypericin, enhancing commercial production for treatments like HyBryte™ and SGX302.